Endothelin receptor antagonists

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) pathogenesis involves three key pathways: endothelin (ET), nitric oxide (NO), and prostacyclin.
• These pathways are critical targets for current PAH therapies, advancing treatment and understanding.
• The ET system, acting through ETA and ETB receptors, significantly contributes to PAH pathophysiology.

Purpose of the Study:

• To elucidate the role of the endothelin system in PAH pathogenesis.
• To review experimental data on ET's involvement in PAH.
• To examine the clinical efficacy and status of endothelin receptor antagonists (ERAs) in PAH treatment.

Main Methods:

• Review of experimental data concerning the endothelin system in PAH.
• Analysis of the pathophysiology of PAH focusing on the ET pathway.
• Examination of clinical trial data for approved and investigational ERAs.

Main Results:

• The ET system plays a well-established, detrimental role in PAH.
• Endothelin receptor antagonists (ERAs) are a key component of PAH therapy.
• A novel ERA has recently undergone Phase III clinical investigation.

Conclusions:

• The ET pathway is central to PAH pathogenesis and a validated therapeutic target.
• ERAs represent an important class of drugs for managing PAH.
• Continued research and development of ERAs offer promise for improved PAH treatment outcomes.